Pharma News

The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.

The biopharmaceutical company Ardelyx has licensed to Sanofi its novel phosphate transport NaP2b inhibitor program (also known as NaPi2b, Npt2b and SLC34A2). Ardelyx will receive an undisclosed upfront payment from Sanofi. Total development and...

Daiichi Sankyo Company Limited reports its consolidated subsidiary, Ranbaxy Laboratories, has announced that it has temporarily suspended shipments of active pharmaceutical ingredients (APIs) produced at its Toansa and Dewas plants in India....

AstraZeneca has received FDA approval for its new chemical entity, the orphan drug Myaleptâ„¢ (metreleptin for injection), which is indicated as an adjunct to diet as replacement therapy for the treatment of complications of leptin deficiency...

The Australian pharmaceutical company Alchemia Limited has appointed Thomas Liquard as chief executive officer following the departure of Charles Walker. Liquard, who joined Alchemia in December 2013 as chief operating officer, brings ...

Andromeda Biotech Ltd. has formed an agreement with Teva Pharmaceutical Industries Ltd. for the acquisition of Teva's rights for Andromeda's drug, DiaPep277®  for the treatment of Type 1 diabetes. According to the agreement, Teva will...

Pfizer and Merck & Co. have agreed to explore the therapeutic potential of Merck's investigational anti-PD-1 therapy, MK-3475, in combination with two Pfizer oncology assets. A Phase I/II clinical study will evaluate the safety and...